Dr. Reddy's Laboratories Launches Generic Version of Bloxiverz in the US Market
13 September 2018 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched of Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz (Neostigmine Methylsulfate) Injection approved by the US Food and Drug Administration (USFDA), the company said.

The Bloxiverz brand and generic had US sales of approximately USD 111m MAT for the most recent twelve months ending in July 2018 according to IMS Health.

Dr. Reddy's Neostigmine Methylsulfate Injection, USP is available in 5 mg/10 mL and 10 mg/10 mL multi-dose vials.

Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. The company's major markets include USA, India, Russia and CIS countries, and Europe.